Feb. 7, 2025 — A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 ...

Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

The global aerosol delivery devices market was valued at $31,463.9 million in 2019, and is projected to reach $46,728.7 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Rise in ...

Timing the use of a commonly prescribed asthma inhaler in the mid-afternoon could lead to improved clinical outcomes, ...

smart inhalers market report highlights transformative digital innovations in respiratory care, improved patient adherence, and forecasted growth through 2035 ...

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

Homelessness leads to higher rates of respiratory disease and lower life expectancy, but there are people fighting to turn ...

Editor’s Note: BuzzFeed does not support discriminatory or hateful speech in any form. We recognize that X is no longer a safe platform. Despite this, it remains a discussion hub where ...

Consult your doctor before starting or stopping a therapy. One of my comorbidities is arthritis ... I’ve found the medication to be quite effective in improving my sleep. The one symptom of COPD I ...

Chronic obstructive pulmonary disease, or COPD, affects more than 30 million Americans. It is the fourth leading cause of death worldwide. But many have never heard of it. The COPD Foundation is ...

Background Some patients with COPD report frequent acute exacerbations (AECOPD) of the disease (FE), whereas others suffer them infrequently (IE). Because the current diagnosis of exacerbation relies ...

A recently approved triple-therapy combination — fluticasone furoate, umeclidinium, and vilanterol (FF+UMEC+VI) — in a single inhaler was found to be associated with improved asthma control in ...